Retour

Genfit S.A.

Qualité des données : 100%

GNFTF

OTC Healthcare Biotechnology

10,43 €

▼ 0,45 € (-4,14%)

Cap. Boursière : 521,88M

Fourchette du Jour

10,43 € 10,88 €

Fourchette 52 Semaines

3,28 € 10,88 €

Volume

500

Moyenne 50J / 200J

8,14 € / 4,95 €

Clôture Précédente

10,88 €

Quick Summary

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (631 pairs)

Métrique	Action	Médiane du Secteur
P/E	346,3	0,2
P/B	7,5	3,0
ROE %	2,2	3,6
Net Margin %	2,3	3,8
Rev Growth 5Y %	205,9	9,7
D/E	0,9	0,2

Objectif de Cours des Analystes

Aucune couverture d'analyste disponible

Estimations de Bénéfices

Période	BPA Est.	CA Est.	Analystes
FY2029	-0,34 € -0,52 € – -0,18 €	63,12M	1
FY2028	0,17 € 0,09 € – 0,27 €	84,02M	1
FY2027	0,60 € 0,33 € – 0,93 €	98,74M	1

Earnings Surprises

Last 8 quarters

Quarter	Est. EPS	Actual EPS	Surprise
2025-04-24	-0,24 €	-0,58 €	-138,3%
2024-09-19	0,33 €	0,50 €	+51,2%
2024-04-04	1,35 €	-0,16 €	-112,0%
2023-12-30	N/A	-0,15 €	—
2023-09-20	-0,39 €	-0,42 €	-7,6%
2023-04-13	-1,08 €	-0,27 €	+75,2%
2022-12-31	N/A	-0,12 €	—
2022-09-28	-0,23 €	-0,21 €	+9,0%

Dividend History

Yield

0,00%

Payout Ratio

0,00%

Growth (3Y)

N/A

Growth (5Y)

N/A

No dividend history available.

Points Clés

Revenue grew 205,92% annually over 5 years — strong growth

ROE of 2,20% is below average

Generating 14,22M in free cash flow

P/E of 346,31 — premium valuation

Revenue growth is decelerating — 1Y growth trails 5Y average by 71,36%

Cash machine — converts 943,66% of earnings into free cash flow

Croissance

Revenue Growth (5Y)

205,92%

Revenue (1Y)134,56%

Earnings (1Y)N/A

FCF Growth (3Y)N/A

Qualité

Return on Equity

2,20%

ROIC1,87%

Net Margin2,25%

Op. Margin4,90%

Sécurité

Debt / Equity

0,90

Current Ratio1,23

Interest Coverage0,69

Valorisation

P/E Ratio

346,31

Forward P/E46,14

P/B Ratio7,54

EV/EBITDA153,07

Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y)	134,56%	Revenue Growth (3Y)	82,15%
Earnings Growth (1Y)	N/A	Earnings Growth (3Y)	N/A
Revenue Growth (5Y)	205,92%	Earnings Growth (5Y)	N/A
Profitability
Revenue (TTM)	67,00M	Net Income (TTM)	1,51M
ROE	2,20%	ROA	1,00%
Gross Margin	99,55%	Operating Margin	4,90%
Net Margin	2,25%	Free Cash Flow (TTM)	14,22M
ROIC	1,87%	FCF Growth (3Y)	N/A
Safety
Debt / Equity	0,90	Current Ratio	1,23
Interest Coverage	0,69
Dividends
Dividend Yield	0,00%	Payout Ratio	0,00%
Dividend Growth (3Y)	N/A	Dividend Growth (5Y)	N/A
Consecutive Div Years	N/A
Valuation
P/E Ratio	346,31	Forward P/E	46,14
P/B Ratio	7,54	P/S Ratio	7,79
PEG Ratio	-1,08	Forward PEG	N/A
EV/EBITDA	153,07	Fwd EV/EBITDA	N/A
Forward P/S	6,87	Fwd Earnings Yield	2,17%
FCF Yield	2,72%
Market Cap	521,88M	Enterprise Value	502,23M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	67,00M	28,57M	20,20M	80,07M	765 000,0
Net Income	1,51M	-28,89M	-23,72M	67,26M	-101,22M
EPS (Diluted)	0,03	-0,58	-0,48	1,23	-2,60
Gross Profit	66,70M	28,22M	19,95M	79,91M	563 000,0
Operating Income	3,28M	-26,58M	-27,29M	31,82M	-82,90M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Total Assets	151,42M	173,87M	215,54M	281,72M	198,61M
Total Liabilities	82,20M	105,92M	121,01M	162,62M	214,78M
Shareholders' Equity	69,22M	67,95M	94,53M	119,10M	-16,16M
Total Debt	62,13M	70,18M	75,28M	74,24M	185,69M
Cash & Equivalents	81,79M	77,79M	136,00M	258,76M	171,03M
Current Assets	92,77M	113,12M	158,46M	268,10M	184,72M
Current Liabilities	75,16M	38,48M	39,37M	62,84M	31,07M